Division of Biomedical Research, Medical University of Vienna, Austria; Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.
Division of Biomedical Research, Medical University of Vienna, Austria; Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria.
Acta Biomater. 2015 Jan;11:104-13. doi: 10.1016/j.actbio.2014.09.003. Epub 2014 Sep 10.
Biodegradable vascular grafts with sufficient in vivo performance would be more advantageous than permanent non-degradable prostheses. These constructs would be continuously replaced by host tissue, leading to an endogenous functional implant which would adapt to the need of the patient and exhibit only limited risk of microbiological graft contamination. Adequate biomechanical strength and a wall structure which promotes rapid host remodeling are prerequisites for biodegradable approaches. Current approaches often reveal limited tensile strength and therefore require thicker or reinforced graft walls. In this study we investigated the in vitro and in vivo biocompatibility of thin host-vessel-matched grafts (n=34) formed from hard-block biodegradable thermoplastic polyurethane (TPU). Expanded polytetrafluoroethylene (ePTFE) conduits (n=34) served as control grafts. Grafts were analyzed by various techniques after retrieval at different time points (1 week; 1, 6, 12 months). TPU grafts showed significantly increased endothelial cell proliferation in vitro (P<0.001). Population by host cells increased significantly in the TPU conduits within 1 month of implantation (P=0.01). After long-term implantation, TPU implants showed 100% patency (ePTFE: 93%) with no signs of aneurysmal dilatation. Substantial remodeling of the degradable grafts was observed but varied between subjects. Intimal hyperplasia was limited to ePTFE conduits (29%). Thin-walled TPU grafts offer a new and desirable form of biodegradable vascular implant. Degradable grafts showed equivalent long-term performance characteristics compared to the clinically used, non-degradable material with improvements in intimal hyperplasia and ingrowth of host cells.
具有足够体内性能的可生物降解血管移植物将比永久性不可降解假体更具优势。这些构建物将被宿主组织不断取代,导致内源性功能性植入物,该植入物将适应患者的需求,并且仅表现出有限的微生物移植物污染风险。足够的生物力学强度和促进快速宿主重塑的壁结构是可生物降解方法的前提。目前的方法通常显示出有限的拉伸强度,因此需要更厚或增强的移植物壁。在这项研究中,我们研究了由硬段可生物降解热塑性聚氨酯(TPU)制成的薄宿主血管匹配移植物(n=34)的体外和体内生物相容性。膨体聚四氟乙烯(ePTFE)导管(n=34)作为对照移植物。在不同时间点(1 周;1、6、12 个月)取出后,通过各种技术分析移植物。TPU 移植物在体外表现出明显增加的内皮细胞增殖(P<0.001)。植入后 1 个月内,TPU 导管中的宿主细胞数量显著增加(P=0.01)。长期植入后,TPU 植入物显示 100%通畅率(ePTFE:93%),没有动脉瘤扩张的迹象。可降解移植物观察到实质性重塑,但个体之间存在差异。内膜增生仅限于 ePTFE 导管(29%)。薄壁 TPU 移植物提供了一种新的、理想的可生物降解血管植入物形式。与临床上使用的不可降解材料相比,可降解移植物具有改善的内膜增生和宿主细胞向内生长的同等长期性能特征。